|
Tissue Genesis Competitive Advantage
Tissue Genesis targets products that have certain attributes
that make them more cost efficient and effective than
products currently being used or published. For cell
culture platforms, techniques and adipose-derived therapeutic
cells, we believe there is no other system on the market
with as much functionality or cost efficiency which
includes:
- a customizable platform that can be adapted for
different products and applications
- automation that reduces manual manipulation and
contamination
- efficient use of space due to compact size
- remote monitoring and system control interfaces
- injection of media and drugs automatically
- “on demand” daily samples and programmed fraction
collection.
Unlike other wound care solutions, such as Apligraf™
and Dermagraf™, the company’s application uses the
patient’s own microvascular endothelial and stem cells.
Additionally, we believe that Tissue Genesis’ vascular
grafts are the only cell lined grafts or vessels that
can be produced using the patient’s own harvested
cells within a matter of hours. Tissue Genesis’ enabling,
proprietary technique is based on patented and patent
pending processes. There are several companies that
have tissue generated grafts made of various materials
either in development, in trials or on the market.
Tissue Genesis’ competitive advantage is that its
graft has an extremely short development time enabling
patients to receive their wound dressing or graft
the same day they enter the hospital. The company
anticipates that the cost of the Tissue Genesis wound
care solution and graft will be competitive with the
cost of current methods of providing other wound dressings
and vessel replacements.
|
|
Tissue Genesis Solution
Tissue Genesis is the exclusive licensee to adipose
(fat) derived therapeutic cell technology developed
by Dr. Stuart Williams PhD, at Thomas Jefferson University.
This technology includes the pioneering method for
derivation of these cells, and various applications
of theses cells.
In Tissue Genesis’ patented process, a small amount (about 60cc) of a patient’s adipose (fat) tissue is needle-liposuctioned and processed into a pellet of therapeutic cells, including micro-vascular endothelial cells, stem cells and other regenerative cells. These cells can be delivered back to the patient in a self dissolving wound dressing, can be coated onto a vascular graft or stent, or can be directly injected into damaged tissue, such a damaged heart tissue.
Tissue Genesis has developed the Bio-Optimization
System (BOS), a proprietary platform that accelerates
cell expansion and adhesion in a small, automated,
self contained, closed system. The BOS platform
utilizes a proprietary cell-culture enabling
technology with broad application across the
cell culture and tissue engineering markets.
This platform has been developed specifically
for the production of products for human implantation,
but its flexible design facilitates additional
applications including basic research and development.
The system consists of a set of six cartridges
that each house a disposable biochamber and
disposable flowpath cartridge, all contained
in one unit, the docking station, which is the
size of a breadbox.
Leveraging off the BOS technology, the company
is developing specific clinical products to
address needs in certain market segments.
When available, the TGI 100™ kit, TGI 1000™
system, and TGI 1001™ system will be operating
room compatible applications that will allow
doctors to process adipose tissue, liposuctioned
from a patient, deriving the therapeutic cells
for immediate implantation back into the patient.
The initial applications include wound dressings,
endothelialized ePTFE grafts for kidney
dialysis, cardiovascular and peripheral vascular
markets, and direct injection into damaged
tissue.
The Tissue Genesis therapeutic cell coated
grafts are targeted to compete with currently
used AV fistulae or catheters in the renal dialysis
market, saphenous veins used in CABG surgeries
and alternatives used in peripheral bypass graft
procedures. The Tissue Genesis graft is expected
to offer a longer patency rate and a cost effective
alternative in these markets due to the use
of the patient’s own endothelial cell lining
of the graft. Using Tissue Genesis’ proprietary
cell sodding technology with the Tissue Genesis
BOS line of products, a patient’s own therapeutic
cells will be extracted and used to create a
cell-lined vessel for surgical implantation
in a matter of hours.
Mid-graft gross morphology of endothelialized
(left) and control (right) ePTFE grafts after
three month implantation in a canine carotid
segmental replacement model.
|
|
|